Although other studies have assessed the predictive value of different brain markers on longitudinal cognitive decline in Alzheimer’s disease (for reviews see Chandra et al., 2019; Melis et al., 2019), this study compared the three biomarkers simultaneously (i.e. tau pathology, neuroinflammation, brain atrophy) in patients with amyloid-positive MCI and Alzheimer’s dementia. This evidence concerns the gene MAPT and amyloidosis.